Biohaven Pharmaceutical files to sell 115,836 shares of common stock for holders 17:0303/0503/05/21
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho » 06:4903/0203/02/21
Mizuho analyst Vamil…
Mizuho analyst Vamil Divan lowered the firm's price target on Axsome Therapeutics to $118 from $120 and keeps a Buy rating on the shares following the company's Q4 results. The analyst expects AXS-05 to obtain a Priority Review, and expects the stock to rise as investors come to appreciate AXS-05's potential.
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho » 06:4803/0203/02/21
Mizuho analyst Vamil…
Mizuho analyst Vamil Divan raised the firm's price target on Biohaven Pharmaceutical to $103 from $93 and keeps a Buy rating on the shares following the company's :strong" Q4 results.
|Over a week ago|
Biohaven price target raised to $110 from $90 at Piper Sandler » 12:0803/0103/01/21
Piper Sandler analyst…
Piper Sandler analyst Tyler Van Buren raised the firm's price target on Biohaven Pharmaceutical to $110 from $90 and keeps an Overweight rating on the shares following the company's Q4 results. "By anyone's standards, Biohaven's launch of Nurtec over the past year has been extremely effective," Van Buren tells investors in a research note. With 89% commercial coverage, leads in new and productive prescribers, and a likely Q2 prevention approval, Biohaven might be able to attain a leading share against competitor Ubrelvy by end of the year, says the analyst.
Cowen to hold a virtual conference » 09:0703/0103/01/21
QGEN, SLN, BIIB, AXSM, GBT, OCUL, ACAD, PACB, ZTS, QTNT, DVAX, OTRK, ARQT, PFE, BLFS, CHRS, SAGE, CERS, EXEL, ALNY
41st Annual Healthcare…
41st Annual Healthcare Virtual Conference will be held on March 1-4 beginning at 9:10 am on March 1. Webcast Link
Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) » 07:3203/0103/01/21
Reports Q4 revenue…
Reports Q4 revenue $35.1M, consensus $28.23M.
Axsome Therapeutics announces 2021 anticipated milestones » 07:0403/0103/01/21
Anticipated Milestones NDA Submissions: AXS-07 for the acute treatment of migraine, submission early 2Q 2021. Clinical Trial Readouts: Phase 2 MERIT trial of AXS-05 in TRD, topline data 2H 2021. Clinical Trial Initiations: Phase 3 trial of AXS-12 in the treatment of narcolepsy 2Q 2021. FDA Meetings: AXS-14 for fibromyalgia 2Q 2021; AXS-05 for smoking cessation 3Q 2021.
Axsome Therapeutics expects cash to fund operations into at least 2024 » 07:0303/0103/01/21
Axsome expects that its…
Axsome expects that its operating expenses will increase year over year in 2021 to support continued pipeline advancement and build-out of the commercial function. Axsome believes that its cash at December 31, 2020, along with the remaining committed capital from the $225 million term loan facility, is sufficient to fund anticipated operations, based on the current operating plan which includes costs for the commercial launch of AXS-05 in MDD and AXS-07 in migraine, into at least 2024.
Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) » 07:0203/0103/01/21
"The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported positive results from the pivotal ADVANCE-1 trial of AXS-05 in Alzheimer's disease agitation, initiated the second pivotal trial of AXS-05 in this indication, received two new FDA Breakthrough Therapy designations, and built out our commercialization infrastructure," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "So far this year, we have submitted to the FDA the NDA for AXS-05 in major depressive disorder, and are nearing submission of the NDA for AXS-07 in the acute treatment of migraine, which is expected early in the second quarter. Our focus for the remainder of the year will be on the regulatory activities surrounding these NDAs, launch readiness to ensure a successful transition to commercialization, assuming product approvals, and continued advancement of the rest of our differentiated late-stage CNS pipeline."
Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains » 07:3302/2202/22/21
Biohaven Pharmaceutical Holding Company announced that a hyperimmune globulin mimic developed with Biohaven's proprietary MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains known as the "English" and "South African" variants. The preliminary experiments, conducted by Biohaven Labs and an academic collaborator demonstrated that BHV-1200 substantially reduced viral entry into cells. Accelerated development of the COVID-19 MATE program has been supported by the Bill and Melinda Gates Foundation. Vlad Coric M.D., CEO of Biohaven commented, "The battle against COVID-19 -like the virus itself-is dynamic and ever changing. Prophylactic and therapeutic agents with broad specificity against current and future strains will be essential in this ongoing fight to beat the virus. Results from our recent preclinical testing are an exciting advancement for this platform technology, and shows that our lead novel MATE conjugate, BHV-1200, exhibits broad and potent antiviral activity against not only wild type SARS-CoV-2 spike protein but also against mutations of growing clinical relevance, such as those associated with reduced susceptibility to therapeutic monoclonal antibodies and recent SARS-CoV-2 strains." Dr. Coric added, "We believe that BHV-1200 could lead to enhanced efficacy and other benefits over convalescent plasma and alternative antibody-based approaches. Biohaven is excited to advance BHV-1200 into a full clinical development program. We are deeply grateful to the vision and critical funding support provided by The Bill & Melinda Gates Foundation that has accelerated this novel technology towards the clinic."